Shots:

• Amgen to acquire Otezla for $13.4B in cash and will receive its related intellectual property including patents primarily covering apremilast with all assets and liabilities related to Otezla along with Celgene’s employees associated with the Otezla
• BMS to divest Otezla in order to get regulatory approval for its pending Celgene merger. The closing of the acquisition of Otezla is contingent on FTC’s blessing on the BMS & Celgene’s pending merger- its closing and the satisfaction of other closing conditions. BMS is expected to complete its pending merger in H2’19
• Otezla is a selective PDE4 inhibitor- inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. plaque psoriasis for whom phototherapy or systemic therapy is appropriate

Click here to­ read full press release/ article | Ref: BMS | Image: Quape